CIK 0001425205
- Accelerated filer
IOVANCE BIOTHERAPEUTICS, INC.
Sign in to watch- Ticker
- IOVA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 753254381
- Phone
- +1 650-260-7120
- Business address
- 825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070
- Former names
- Lion Biotechnologies, Inc., Genesis Biopharma, Inc, FREIGHT MANAGEMENT CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 99 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-01 | WEISER MICHAEL Director | Grant or award · Deferred Restricted Stock Unit | +100,000 | 100,000 | ||
| 2024-03-01 | MCPEAK MERRILL A Director | Grant or award · Deferred Restricted Stock Unit | +50,000 | 50,000 | ||
| 2024-03-01 | Dukes Iain D. Director | Grant or award · Deferred Restricted Stock Unit | +100,000 | 100,000 | ||
| 2024-03-01 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Grant or award · Restricted Stock Units | +105,470 | 105,470 | ||
| 2024-03-01 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Grant or award · Restricted Stock Units | +46,875 | 46,875 | ||
| 2024-03-01 | BILINSKY IGOR Chief Operating Officer | Grant or award · Restricted Stock Units | +105,470 | 105,470 | ||
| 2024-03-01 | BILINSKY IGOR Chief Operating Officer | Grant or award · Restricted Stock Units | +46,875 | 46,875 | ||
| 2024-03-01 | Bellemin Jean-Marc Chief Financial Officer | Grant or award · Restricted Stock Units | +105,470 | 105,470 | ||
| 2024-03-01 | Bellemin Jean-Marc Chief Financial Officer | Grant or award · Restricted Stock Units | +46,875 | 46,875 | ||
| 2024-03-01 | Countouriotis Athena Director | Grant or award · Deferred Restricted Stock Unit | +50,000 | 50,000 | ||
| 2024-02-20 | MCPEAK MERRILL A Director | Purchase | +250,000 | $9.15 | $2.3M | 320,150 |
| 2024-02-20 | Dukes Iain D. Director | Purchase | +32,000 | $9.15 | $293K | 54,000 |
| 2024-02-20 | Rothbaum Wayne P. Director | Purchase | +5,000,000 | $9.15 | $45.8M | 28,067,333 |
| 2024-01-16 | Vogt Frederick G Interim CEO & General Counsel | Option exercise | +20,834 | 105,668 | ||
| 2024-01-16 | Vogt Frederick G Interim CEO & General Counsel | Shares withheld for taxes | −6,530 | $8.37 | $55K | 99,138 |
| 2024-01-16 | Vogt Frederick G Interim CEO & General Counsel | Option exercise · Restricted Stock Units | −20,834 | 83,338 | ||
| 2024-01-16 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Option exercise | +2,813 | 35,184 | ||
| 2024-01-16 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Shares withheld for taxes | −1,577 | $8.37 | $13K | 33,607 |
| 2024-01-16 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Option exercise · Restricted Stock Units | −2,813 | 11,251 | ||
| 2024-01-16 | BILINSKY IGOR Chief Operating Officer | Option exercise | +2,813 | 31,444 |
Page 16 of 23 · 446 trades